Background
==========

Coronary artery disease (CAD), one of the most common cardiovascular diseases, ranks first among fatal diseases in adults around the world \[[@b1-medscimonit-22-8]--[@b3-medscimonit-22-8]\]. Several risk factors have been confirmed, such as smoking, hypertension, diabetes, high blood cholesterol, excessive alcohol drinking, depression, and lack of exercise \[[@b4-medscimonit-22-8],[@b5-medscimonit-22-8]\]. As for the underlying mechanism of CAD, it is reported that cardiac atherosclerosis may have a significant influence on the occurrence and progression of the disease \[[@b6-medscimonit-22-8],[@b7-medscimonit-22-8]\]. However, genetic and environmental risk factors have been widely researched in the etiology of CAD, and their remarkable effects on susceptibility to CAD have also been identified.

In recent years, accumulating evidence indicates that genetic polymorphisms may be implicated in individual susceptibility to CAD, including polymorphisms within genes of *APLNR* \[[@b8-medscimonit-22-8]\], interleukin-6 \[[@b9-medscimonit-22-8]\], *CYP7A1* \[[@b10-medscimonit-22-8]\], and *PAI-1* \[[@b11-medscimonit-22-8]\]. In addition, the apolipoprotein M gene (*ApoM*), located on human chromosome 6 p21.31, has been reported to be significantly related to the occurrence of CAD \[[@b12-medscimonit-22-8]\].

The *ApoM* gene codes a 22-kDa protein that belongs to the apolipoprotein superfamily in structure. ApoM protein was first identified and determined in a study on lipoprotein by Xu et al. in 1993 \[[@b13-medscimonit-22-8]\]. Human ApoM cDNA, with 734 base pairs, encodes a residue-long protein with 188 amino acids \[[@b14-medscimonit-22-8]\]. ApoM is reportedly related to lower high-density lipoprotein (HDL) cholesterol, triglyceride-rich lipoproteins, lipoproteins containing ApoB, and very low-density lipoprotein (VLDL). Only expressed in the kidneys and liver \[[@b15-medscimonit-22-8]\], ApoM has been confirmed to have great influence on the transportation of reverse cholesterol \[[@b16-medscimonit-22-8]\].

Previous studies have suggested that one of the polymorphisms in *ApoM* gene, rs805296, was related to the susceptibility to CAD \[[@b17-medscimonit-22-8]--[@b20-medscimonit-22-8]\]; however, the number of studies is relatively limited, and the results are divergent rather than conclusive due to various reasons. Therefore, we comprehensively summarized all the findings on the association of *ApoM* rs805296 polymorphism with risk of CAD so as to reach a more authentic conclusion by performing the present meta-analysis.

Material and Methods
====================

Study source and search strategy
--------------------------------

The electronic databases searched for all the usable studies were: PubMed, EMBASE, and Chinese National Knowledge Infrastructure (CNKI). The words and items for literature searching contained "Apolipoprotein M" or " ApoM, "polymorphism" or "variant" or "mutation", and "coronary artery disease" or "CAD" or "atherosclerosis". In case of missing any adequate studies, we screened the articles in the reference lists of relevant studies by manual searching. All the studies were restricted to those in English or Chinese.

Selection standards
-------------------

All the publications meeting the following requirements were included into our meta-analysis: (1) possessing the case and control subjects at the same time; (2) studying the correlation between *ApoM* rs805296 polymorphism and CAD risk; (3) with sufficient data describing genotype and allele frequencies of the polymorphism in case and control groups; (4) human studies; and (5) the genotype distribution in control group conforming to Hardy-Weinberg equilibrium. Those studies with case-only design, inadequate information, or duplicating other articles were excluded. For publications with similar datasets, the one with the largest amount of information was included.

Data extraction
---------------

An identical form for data extraction was designed in advance, and the whole process was completed by 2 authors separately. Information to be extracted from each included article incorporated the following aspects: year of publication, name of first author, country of origin, ethnicity, genotyping method, sample sizes of cases and controls, genotypic and allelic distribution in case and control groups, and *P* value for Hardy-Weinberg equilibrium in control group.

Statistical analyses
--------------------

STATA software (V.12.0) was used in all statistical analyses. Since all the publications would have control groups with genotypic and allelic frequencies consistent with Hardy-Weinberg equilibrium according to the selection criteria, we checked the compliance degree of Hardy-Weinberg equilibrium using the chi-square test for those not stating relevant data. The strength of relationship between *ApoM* rs805296 polymorphism and CAD risk was evaluated with odds ratio (OR) and its corresponding 95% confidence interval (95% CI) under 5 genetic models (CC versus TT, CC + TC versus TT, CC versus TT+TC, C versus T and TC versus TT). The absence or presence of statistically significant inter-study heterogeneity, tested by the χ^2^-test-based Q statistic, determined the use of fixed-effects model (Mantel-Haenszel method) or random-effects model (DerSimonian and Laird method). In sensitivity analysis, each single study was deleted in turn to observe the alterations of the overall results. Through Begg's funnel plots and Egger's test, we detected if there existed significant publication bias across eligible studies. For all the statistical tests, the significance level was set at *P*\<0.05.

Results
=======

Publication characteristics
---------------------------

[Figure 1](#f1-medscimonit-22-8){ref-type="fig"} displays the detailed process of study selection and reasons for study exclusion. Initially, 81 records were identified through the computer search, and 36 remained after excluding 8 studies not on humans and 37 apparently irrelevant ones. Through the subsequent exclusion for reviews and letters (7), without full texts (3), duplicates (5), not about *ApoM* rs805296 polymorphism (8) and without original data (6), we eventually included 7 studies in the quantitative synthesis \[[@b18-medscimonit-22-8],[@b21-medscimonit-22-8]--[@b26-medscimonit-22-8]\]. The primary features of eligible studies are presented in [Table 1](#t1-medscimonit-22-8){ref-type="table"}.

Study results
-------------

[Table 2](#t2-medscimonit-22-8){ref-type="table"} shows the ORs with 95% CIs and *P* values for heterogeneity test under all the genetic models. Overall, the *ApoM* rs805296 polymorphism elevated the CAD risk in all the genetic contrasts (CC versus TT: OR=2.13, 95% CI=1.16--3.91; CC + TC versus TT: OR=1.80, 95% CI=1.50--2.17; CC versus TT+TC: OR=1.91, 95% CI=1.04--3.51; C versus T: OR=1.72, 95% CI=1.45--2.04; TC versus TT: OR=1.78, 95% CI=1.47--2.15). [Figure 2](#f2-medscimonit-22-8){ref-type="fig"} describes the forest plot for the association of *ApoM* rs805296 polymorphism with CAD risk under the CC versus TT model.

Heterogeneity examination
-------------------------

As shown in [Table 2](#t2-medscimonit-22-8){ref-type="table"}, *P* values for heterogeneity under all the genetic models were larger than 0.05 (*P*=0.491 for CC versus TT model; *P*=0.204 for CC + TC versus TT model; *P*=0.557 for CC versus TT+TC model; *P*=0.126 for C versus T model; *P*=0.361 for TC versus TT model). Therefore, there was no marked heterogeneity and the fixed-effects model was used for pooling the results.

Publication bias test
---------------------

Begg's funnel plots and Egger's test were used to detected possible publication bias among the included studies from the visual and statistical perspective, respectively, and neither the shapes of funnel plots ([Figure 3](#f3-medscimonit-22-8){ref-type="fig"}) nor the statistical data of Egger's test (*P*=0.260) provided evidence for the presence of obvious publication bias.

Sensitivity analysis
--------------------

In the process of sensitivity analysis, every individual study was omitted in sequence, and the changed results were observed correspondingly. No radical alteration occurred in the pooled results, suggesting that no single study substantially affected the results, and our meta-analysis outcomes were statistically robust.

Discussion
==========

CAD is a complex multi-genetic disease caused by synergistic effects of genetic and environmental risk factors \[[@b27-medscimonit-22-8],[@b28-medscimonit-22-8]\]. Hereditary epidemiological studies have suggested that genetic mutations may elevate individual risk of developing CAD \[[@b29-medscimonit-22-8]--[@b31-medscimonit-22-8]\]. Initially separated and cloned from chylomicrons \[[@b13-medscimonit-22-8]\], ApoM in plasma mainly exists in HDL particles, and very little is in triglyceride-rich lipoprotein (TGRLP) and low-density lipoprotein (LDL), suggesting ApoM may be associated with lipid transportation and metabolism \[[@b15-medscimonit-22-8]\]. Richter et al. found an important role of ApoM in the formation of HDL, and confirmed its protective effects against atherosclerosis \[[@b16-medscimonit-22-8],[@b32-medscimonit-22-8]\]. In the study by Xu et al., the correlation between ApoM and indexes of lipid indicated that ApoM levels in plasma had a positive relation with factors against the progression of atherosclerosis, such as ApoA I and HDLC, and was negatively related with factors promoting atherosclerosis development, such as triglyceride, total cholesterol, and lipoprotein (a), and that elevated levels of ApoM could prevent and slow the progression of atherosclerosis \[[@b33-medscimonit-22-8]\].

The human *ApoM* gene is located in a region adjacent to that of major histocompatibility complex (MHC) in which multiple genes are related to immune response; therefore, the *ApoM* gene is likely to participate in the regulation of immune defense \[[@b34-medscimonit-22-8]\]. Among a number of polymorphisms within the *ApoM* gene, the rs805296 variant in the proximal promoter region has been verified to have a link with plasma cholesterol, and may increase individual susceptibility to CAD \[[@b35-medscimonit-22-8]\].

In this present study, we referred to previous studies and analyzed the association between *ApoM* rs805296 polymorphism and CAD risk. Our results indicate that *ApoM* rs805296 polymorphism under all the comparisons could elevate the risk of CAD, suggesting this polymorphism might act as a promoter for CAD onset. Several case-control studies have investigated the significance of *ApoM* rs805296 in CAD risk in Chinese populations, and obtained useful findings. Using the method of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), Huang et al. carried out a screening for *ApoM* rs805296 in 220 CAD cases and 195 normal controls, and observed the frequency of C allele in case and control groups was 19.1% and 12.6% respectively, and this difference was statistically significant (*P*=0.011), which proved the polymorphism rs805296 might be a susceptible factor for CAD \[[@b21-medscimonit-22-8]\]. Zhang et al. performed a large study recruiting 675 patients with acute coronary syndrome (ACS) and 636 healthy control subjects, and found that the frequencies of both C allele and CC genotype of *ApoM* rs805296 polymorphism in the case group were significantly higher than those in the control group (*P*\<0.01). Subsequently, after the adjustment of susceptibility factors for CAD, the C allele was found to be an independent risk factor for the occurrence of ACS \[[@b25-medscimonit-22-8]\]. In addition, some other studies also obtained results similar to those mentioned above \[[@b18-medscimonit-22-8],[@b22-medscimonit-22-8],[@b23-medscimonit-22-8],[@b26-medscimonit-22-8]\]. In contrast, Zheng et al. found no statistically significant difference in distribution of 3 genotypes of *ApoM* rs805296 polymorphism, including TT, TC, and CC, between case and control groups, and concluded that rs805296 might not be correlated with the development of CAD \[[@b24-medscimonit-22-8]\]. Conducted in a Chinese population, the study of Zheng et al. obtained results that are in contrast with our present study and the other case-control studies listed above, which might be attributed to differences in number of samples, methods of genotyping, correction factors, and other risk elements.

Absence of heterogeneity and publications bias is the biggest strength of this meta-analysis. However, as in previous studies and meta-analyses, our meta-analysis also has some weaknesses that should be clearly presented. Because all the prior studies on the association of *ApoM* rs805296 polymorphism with CAD risk only focused on Chinese populations, our meta-analysis solely discussed this association among Chinese people, which might not be representative in other ethnic groups. In addition, the limited number of included studies and the relatively small sample size might lessen the statistical power of our results. Another important aspect that should be stated is that some potential risk factors such as family history, smoking status, body mass index (BMI) and other environmental influences \[[@b36-medscimonit-22-8]\] were not incorporated into the discussion of the present study due to limited original information of included studies.

Conclusions
===========

In conclusion, our meta-analysis results revealed a significant correlation of *ApoM* rs805296 polymorphism with CAD risk, and showed rs805296 polymorphism might confer increased risk of CAD in the Chinese population. The association between *ApoM* rs805296 and onset risk of CAD needs to be further verified by studies containing combined effects of genetic and environmental factors and larger sample size in multiple ethnicities.

**Source of support:** Departmental sources
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###### 

Main information extracted from eligible studies in the meta-analysis.

  Author/year   Country   Ethnicity   Control source   Genotyping method     Case   Control   P (HWE)                                                      
  ------------- --------- ----------- ---------------- --------------------- ------ --------- --------- ---- ------ ----- ----- ----- ---- --- ------ ---- -------
  Jiao/2007     China     Asian       Hospital-based   PCR-RFLP              118    86        29        3    201    35    225   194   31   0   419    31   0.267
  Huang/2009    China     Asian       Hospital-based   PCR-RFLP              220    145       66        9    356    84    195   150   41   4   341    49   0.548
  Wang/2009     China     Asian       Hospital-based   PCR-RFLP              45     29        15        1    73     17    60    51    9    0   111    9    0.530
  Zheng/2009    China     Asian       Hospital-based   Real-time PCR         126    99        25        2    223    29    118   100   18   0   218    18   0.370
  Ma/2011       China     Asian       Hospital-based   Allele-specific PCR   46     28        17        1    73     19    56    47    9    0   103    9    0.513
  Zhang/2012    China     Asian       Hospital-based   PCR-RFLP              675    530       135       10   1195   155   636   556   74   6   1186   86   0.052
  Zheng/2014    China     Asian       Hospital-based   Direct sequencing     206    165       39        2    369    43    209   170   35   4   375    43   0.180

PCR -- polymerase chain reaction; PCR-RFLP -- PCR-restriction fragment length polymorphism; *P* (HWE) -- *P* value for Hardy-Weinberg equilibrium test.

###### 

Meta-analysis results about *APOM* rs805296 polymorphism and CAD risk.

  *APOM* rs805296             CC versus TT   CC + TC versus TT   CC versus TT+TC   C versus T   TC versus TT                                                                                       
  --------------------------- -------------- ------------------- ----------------- ------------ -------------- ------- ------ ------------ ------- ------ ------------ ------- ------ ------------ -------
  Fixed-effects model value   2.13           1.16--3.91          0.491             1.80         1.50--2.17     0.204   1.91   1.04--3.51   0.557   1.72   1.45--2.04   0.126   1.78   1.47--2.15   0.361

*Ph* -- *P* value of heterogeneity test.
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